Gilead Pharmasset LLC

Gilead Sciences, Inc.

Hongmei Mo

Adrian S Ray

William E Delaney, Iv

John O Link

Cheng Yong Yang

David W Oldach

William John Watkins

Dimitrios Stefanidis

Reza Oliyai

Vahid Zia

Rowchanak Pakdaman

Darryl G Cleary

Melissa Jean Casteel

Guofeng Cheng

William T Symonds

Christy M Hebner

Simin Xu

Charles J Reynolds

Miriam Michelle Berrey

Robert G Hindes

Weidong Zhong

Betty Peng

Mei Yu

Amoreena Corsa

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

Methods for treating HCV

Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.

Compositions and methods for treating hepatitis C virus

Replicons of genotype 3 of hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 3 replicons and methods of using these replicons to screen antiviral agents are also provided.

HCV genotype 3 replicons

Replicons of genotype 4 hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 4 replicons and methods of using these replicons to screen antiviral agents are also provided.

HCV genotype 4 replicons

Growing community of inventors

Palo Alto, CA, United States of America

Hongmei Mo